Intrinsic value of Apimeds Pharmaceuticals US, Inc (APUS)
Live fair value data for Apimeds Pharmaceuticals US, Inc (APUS) is currently unavailable. Please check again shortly.
Current Price: $53.00
Valuation: Overvalued
Confidence: 4.0/10
Visual Bar
This intrinsic value is calculated using 5 different models based on projected revenue growth, profit margins, and a standard discount rate.
Is Apimeds Pharmaceuticals US, Inc (APUS) undervalued or overvalued?
Based on the current model output, Apimeds Pharmaceuticals US, Inc appears to be overvalued with a downside of 4.00%.
Fair value vs market price — Apimeds Pharmaceuticals US, Inc (APUS)
Unlock premium access to view the live fair value comparison against current market price for APUS.
Frequently Asked Questions - APUS
How is APUS intrinsic value estimated?
We combine revenue growth, discount rate, and terminal growth assumptions to estimate a fair value range for APUS.
Is APUS undervalued or overvalued right now?
APUS is currently shown as overvalued based on the difference between market price and intrinsic value.
How should I use the confidence score?
The confidence score (0 to 10) indicates model certainty from available inputs. Higher values suggest stronger model consistency, not a guarantee of returns.
Related companies — intrinsic value
Peers for APUS: open their intrinsic value pages.